---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031441"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:03:58.602629+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024

## Summary
- Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.
- Phase 3 EFZO-FIT study in pulmonary sarcoidosis enrollment expected to complete Q2 2024; DSMB allowed unmodified continuation.
- Launched Individual Patient Expanded Access Program for patients completing EFZO-FIT study.
- Phase 2 EFZO-CONNECT study in SSc-ILD enrolling (proof-of-concept, up to 25 patients); multiple U.S. sites open.
- R&D expenses $42.3M, G&A $13.0M for year 2023; no product revenue as clinical-stage biotech.

## SEC filing metadata
- accession: 0000950170-24-031441
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/life-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031441
- JSON: https://secwatch.observer/filing/0000950170-24-031441.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031441.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC updated its the year ended December 31, 2023 guidance (reaffirmed).
  - Period: the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm
- Earnings Releases
  aTYR PHARMA INC updated its the fourth quarter ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.